Assessment
Questionnaire

Have a symptom?
See what questions
a doctor would ask.
 
Diseases » Alzheimer's Disease » Research
 

Cure Research for Alzheimer's Disease

Medications currently used in research into the prevention of Alzheimer's Disease:

Note:You must always seek professional medical advice about any treatment or change in treatment plans.

Some of the different medications being used in the research into prevention of Alzheimer's Disease include:

  • Estrogen
  • Alora
  • C.E.S
  • Climacteron
  • Climara
  • Climestrone
  • Congest
  • Delestrogen
  • Depo-Estradiol
  • DV
  • Esclim
  • Estinyl
  • Estrace
  • Estraderm
  • Estraguard
  • Estratab
  • Extrovis
  • Feminone
  • Femogen
  • Femogex
  • Gynetone
  • Gynodiol
  • Gynogen LA
  • Menest
  • Menotab
  • Oesclim
  • Oestrilin
  • Ogen
  • PMB
  • PMS-Estradiol
  • Premarin
  • Premphase
  • Prempro
  • Progynon Pellet
  • TACE
  • Valergen-10
  • Vivelle
  • Vivelle-Dot
  • White Premarin

Curable Types of Alzheimer's Disease

Possibly curable or rare types of Alzheimer's Disease include:

Rare Types of Alzheimer's Disease:

Some rare types of Alzheimer's Disease include:

Treatments for Alzheimer's Disease

Treatments to consider for Alzheimer's Disease may include:

  • Mental stimulation
  • Tacrine (THA, Cognex)
  • Aricept (donepezil) - reversible acetylcholinesterase inhibitors
  • Exelon (rivastigmine) - reversible acetylcholinesterase inhibitors
  • more treatments...»

Cure Research discussion for Alzheimer's Disease:

Genes and Disease by the National Center for Biotechnology (Excerpt)

Currently, scientists are studying the interrelationship between the various gene loci (particularly the mutation on chromosome 21) and how environmental factors could effect a person's susceptibility to AD. Recently, use of a mouse model of the disease identified an enzyme that may be responsible for the increase in amyloid production characteristic of AD. If a way to regulate this enzyme could be found, then AD may be slowed or halted in some people. (Source: Genes and Disease by the National Center for Biotechnology)

NINDS Alzheimer's Disease Information Page: NINDS (Excerpt)

The NINDS conducts and supports research on neurodegenerative and dementing disorders, including AD. For example, although the cause of AD is still unknown, new research has shown that a vaccine, aimed at preventing or reversing the formation of AD-associated pathologic lesions, might be a useful therapy. Recent results using a transgenic mouse model suggest that immunological interventions may retard and even reverse the development of some of the pathologic changes associated with AD. Early clinical trials to test the vaccine are still in progress but offer hope for a future therapy. The National Institute on Aging and the National Institute of Mental Health also support research related to AD. (Source: excerpt from NINDS Alzheimer's Disease Information Page: NINDS)

NIA's Progress Report on Alzheimer's Disease, 1998: NIA (Excerpt)

Pursuing another avenue, researchers at NIA are looking at Down's syndrome because it shares some traits with AD. Down's syndrome is caused by a birth defect in which the person has three, rather than the normal two, copies of chromosome 21. Down's syndrome is associated with mental retardation and the development of AD pathology. Because the gene for APP has been mapped to chromosome 21, some researchers believe that Down's syndrome is related to the "overexpression" of APP. (Source: excerpt from NIA's Progress Report on Alzheimer's Disease, 1998: NIA)

NIA's Progress Report on Alzheimer's Disease, 1998: NIA (Excerpt)

According to one new theory about the causes for sporadic AD, as neurons age, they may begin to make errors in translating the information contained in the gene's sequence of bases into the correct protein for beta-amyloid, causing a buildup of abnormal proteins in the neuron (van Leeuwen et al., 1998). (Source: excerpt from NIA's Progress Report on Alzheimer's Disease, 1998: NIA)

NIA's Progress Report on Alzheimer's Disease, 1998: NIA (Excerpt)

The researchers found that nuns who had had the infarctions in certain brain regions had more clinical symptoms of dementia than could be explained by the number of plaques and tangles in the cerebral cortex. These findings suggest that at least some brain infarcts, which do not themselves cause dementia, may play an important role in increasing the severity of the clinical signs of AD. In addition, other signs of disease related to the brain's blood vessels or blood supply, such as atherosclerosis, may be involved in the development of AD. Further research is needed to understand whether preventing these types of blood vessel diseases in the brain can help reduce the clinical signs of AD. (Source: excerpt from NIA's Progress Report on Alzheimer's Disease, 1998: NIA)

NIA's Progress Report on Alzheimer's Disease, 1998: NIA (Excerpt)

However, scientists are now studying a new generation of cholinesterase inhibitors, which might have greater usefulness and fewer side effects. In studies on animals, scientists at NIA (Patel et al., 1998) have preliminary evidence suggesting that one such drug, called phenserine, may be useful in treating AD patients. In animal models of cognitive decline, phenserine was significantly more effective in enhancing performance and learning in a maze test than drugs currently marketed to treat AD. Phenserine is undergoing toxicology testing (studies to find safe doses and identify any potentially problematic side effects). And NIA scientists recently found that a drug called arecoline seems to improve cognitive function and the process whereby chemical messages are sent across synapses in animals. Arecoline artificially stimulates acetylcholine receptors. Researchers now are studying the effects of arecoline in people.

Another drug that inhibits acetylcholinesterase, called physostigmine, is helping researchers to understand how these drugs can improve brain functions such as working memory, the form of memory that enables people to hold information such as telephone numbers for a short period of time. NIA researchers (Furey et al., 1997) used PET scans to study the beneficial effect of physostigmine on working memory in humans. Because physostigmine has a shorter duration of action than the drugs that are already approved for AD treatment, researchers are developing a longer-acting form. (Source: excerpt from NIA's Progress Report on Alzheimer's Disease, 1998: NIA)

NIA's Progress Report on Alzheimer's Disease, 1998: NIA (Excerpt)

Oxidative changes are seen in the brains of AD patients. Studies of compounds that fight oxidation are part of the effort to understand processes that damage cells and find ways to treat and possibly prevent AD. The NIA-supported ADCS trial of selegiline (l-deprenyl or Eldepryl) and alpha-tocopherol (vitamin E) is one such study. Both selegiline and vitamin E act as anti-oxidants. Selegiline, which has been used to treat patients with Parkinson's disease, works by inhibiting an enzyme in the brain that impairs certain neurotransmitter systems. (Source: excerpt from NIA's Progress Report on Alzheimer's Disease, 1998: NIA)

NIA's Progress Report on Alzheimer's Disease, 1998: NIA (Excerpt)

There is growing interest in the use of ginkgo biloba extract for the treatment of AD. Ginkgo biloba extract is a traditional Chinese medicine made from the leaves of the ginkgo tree. It apparently has anti-oxidant, anti-inflammatory, and anti-coagulant properties. In the first American trial of ginkgo against AD, the authors (Le Bars et al., 1997) found a "fairly modest" positive effect. However, there have been several reports linking ginkgo to hemorrhages, and other possible side effects are as yet unknown. NIA is funding some investigations into the use of ginkgo in treating AD. (Source: excerpt from NIA's Progress Report on Alzheimer's Disease, 1998: NIA)

NIA's Progress Report on Alzheimer's Disease, 1998: NIA (Excerpt)

Some pharmacological agents already are being tested in human patients. NINDS's Experimental Therapeutics Branch is participating in a multicenter trial of HWA285 (propentofylline). HWA285 is believed to have anti-inflammatory and neuroprotective properties, and it is hoped that it will slow the rate of intellectual decline in patients with dementia. The results of this trial currently are being analyzed. The Branch also is testing Ampalex (CX516, AMPAKINE), a new drug that may improve thinking and memory, in patients with mildly to moderately advanced AD. Ampalex has been shown in preclinical trials to be highly promising in improving cognitive function, and has been relatively free of serious side effects. AMPAKINEs enhance the functioning of a receptor, called the AMPA receptor, which plays a key role in memory formation and communication within and between different regions of the brain. (Source: excerpt from NIA's Progress Report on Alzheimer's Disease, 1998: NIA)

NIA's Progress Report on Alzheimer's Disease, 1998: NIA (Excerpt)

NIMH-supported scientists at the University of Pennsylvania (Streim et al., 1997) recently conducted a double-blind study of regular versus low-dose nortriptyline, an anti-depressant with anti-cholinergic activity. The response to nortriptyline in cognitively intact patients was found to increase with blood levels of the drug within the therapeutic range established in younger and healthier patients. However, patients with AD were less likely to respond and showed no significant relationship between plasma levels and clinical response. These findings suggest that the neuropharmacological processes underlying depression and the responses to anti-depressant medications in cognitively intact older patients are similar to those that are operative in younger and healthier individuals. However, in patients with AD they are quite different. Meeting the mental health needs of patients with AD requires specific knowledge that must be derived from research conducted on this special population. (Source: excerpt from NIA's Progress Report on Alzheimer's Disease, 1998: NIA)

Medical research for Alzheimer's Disease: medical news summaries:

The following medical news items are relevant to medical research for Alzheimer's Disease:

Clinical Trials for Alzheimer's Disease

Some of the clinical trials for Alzheimer's Disease include:

Evidence Based Medicine Research for Alzheimer's Disease

Medical research papers related to Alzheimer's Disease include:

Click here to find more evidence-based articles on the TRIP Database

 

By using this site you agree to our Terms of Use. Information provided on this site is for informational purposes only; it is not intended as a substitute for advice from your own medical team. The information on this site is not to be used for diagnosing or treating any health concerns you may have - please contact your physician or health care professional for all your medical needs. Please see our Terms of Use.

Home | Symptoms | Diseases | Diagnosis | Videos | Tools | Forum | About Us | Terms of Use | Privacy Policy | Site Map | Advertise